Contact Us   Having technical issues or questions regarding this product?
Please Contact Us.
BEI Resources currently limits the total number of "Made to Order" items which can be ordered by a registrant to 10 "Made to Order" items per 6 month period. Please check the Availability Status on the items you are ordering and limit orders appropriately.
NR-36208   Anthrax Protective Antigen (PA), Recombinant from Bacillus anthracis
(Toxins)
Price: All BEI Resources products are provided
at no cost to registered researchers.
Description: Anthrax Protective Antigen (PA), Recombinant from Bacillus anthracis
Organism: Bacillus anthracis
Biosafety Level: 1
Availability Status: In Stock
Store at: 2°C to 8°C prior to reconstitution
Contributor: BEI Resources
Comments:
Quantity limit per order for this item is 1. This item can be ordered twice a year. Orders over this limit will be sent to NIAID for approval before shipment.

Recombinant anthrax protective antigen (PA, 83 kDa) was produced using a plasmid licensed from the NIH. The plasmid was introduced into a non-sporulating avirulent strain of Bacillus anthracis lacking both of the wild type plasmids, pX01 and pX02. Recombinant PA was purified using conventional chromatographic techniques. The resulting purified protein lacks all other anthrax virulence factors.

In vivo, recombinant PA binds to surface receptors on the mammalian cell membrane, and is cleaved by a cellular protease to a 63 kDa protein. When combined with recombinant lethal factor (LF) or edema factor (EF), the cleaved PA binds the toxin enzyme component and mediates its transportation into the cytosol where it exerts its pathogenic effect.

Each vial contains approximately 0.1 mg of recombinant PA. When reconstituted with 0.1 mL of sterile distilled water, the concentration of buffer is 5 mM HEPES (pH 7.5) and 50 mM NaCl. Note: Handle the product gently; DO NOT VORTEX.
Citations: Acknowledgment for publications should read "The following reagent was obtained through BEI Resources, NIAID, NIH: Anthrax Protective Antigen (PA), Recombinant from Bacillus anthracis, NR-36208."
Publications Citing
this Reagent:
Arevalo, M. T., et al. "Targeted Silencing of Anthrax Toxin Receptors Protects against Anthrax Toxins." J. Biol. Chem. 289 (2014): 15730-15738. PubMed: 24742682.

Ballinger, M. N., et al. "Transient Increase in Cyclic AMP Localized to Macrophage Phagosomes." PloS One 5 (2010): e13962. PubMed: 21085604.

Gonzales, C. M., et al. "Antibacterial Role for Natural Killer Cells in Host Defense to Bacillus anthracis." Infect. Immun. 80 (2012): 234-242. PubMed: 22006566.

Gwinn, W. M., et al. "Effective Induction of Protective Systemic Immunity with Nasally-Administered Vaccines Adjuvanted with IL-1." Vaccine 28 (2010): 6901-6914. PubMed: 20723629.

Jiménez-Alberto, A., et al. "Feasibility of the use of ELISA in an immunogenicity-based potency test of anthrax vaccines." Biologicals 39(4): 236-241. PubMed: 21664832.

Lawrence, W. S., et al. "Hemodynamic Effects of Anthrax Toxins in the Rabbit Model and the Cardiac Pathology Induced by Lethal Toxin." Toxins 3 (2011): 721-736. PubMed: 22069736.

Ovsyannikova, I. G., et al. "Human Leukocyte Antigens and Cellular Immune Responses to Anthrax Vaccine Adsorbed." Infect. Immun. 81 (2013): 2584-2591. PubMed: 23649091.

Pflughoeft, K. J., et al. "Modulation of the Bacillus anthracis Secretome by the Immune Inhibitor A1 Protease." J. Bacteriol. 196 (2014): 424-435. PubMed: 24214942.

Quinn, C. P., et al. "A Three-Dose Intramuscular Injection Schedule of Anthrax Vaccine Adsorbed Generates Sustained Humoral and Cellular Immune Responses to Protective Antigen and Provides Long-Term Protection Against Inhalation Anthrax in Rhesus Macaques." Clin. Vaccine Immunol. 19 (2012): 1730-1745. PubMed: 22933399.

Schiffer, J. M., et al. "Quantitative Assessment of Anthrax Vaccine Immunogenicity Using the Dried Blood Spot Matrix." Biologicals 41 (2013): 98-103. PubMed: 23266055.

Semenova, V.A., et al. "Validation and Long Term Performance Characteristics of a Quantitative Enzyme Linked Immunosorbent Assay (ELISA) for Human Anti-PA IgG." J. Immunol. Methods 376 (2012): 97-107. PubMed: 22197974.

Sloat, B. R., M. A. Sandoval and Z. Cui. "Towards Preserving the Immunogenicity of Protein Antigens Carried by Nanoparticles While Avoiding the Cold Chain." Int. J. Pharm. 393 (2010): 197-202. PubMed: 20416366.

Sloat, B. R., et al. "Strong Antibody Responses Induced by Protein Antigens Conjugated onto the Surface of Lecithin-Based Nanoparticles." J. Control. Release 141 (2010): 93-100. PubMed: 19729045.

Stoddard, R. A., et al. "Detection of Anthrax Protective Antigen (PA) Using Europium Labeled Anti-PA Monoclonal Antibody and Time-Resolved Fluorescence." J. Immunol. Methods 408 (2014): 78-88. PubMed: 24857756.

Weiner, Z. P., et al. "Debridement Increases Survival in a Mouse Model of Subcutaneous Anthrax." PLoS One 7 (2012): e30201. PubMed: 22393351
PERMITS
For a list of permits that may be required for shipping this product and to set the permit information preferences; please select a country from the drop down below.

  • Customers located in the state of Hawaii will need to contact the Hawaii Department of Agriculture to determine if an Import Permit is required. A copy of the permit or documentation that a permit is not required must be sent to ATCC in advance of shipment.

Return to Top


Notices and Disclaimers

BEI Resources products are intended for laboratory research purposes only. They are not intended for use in humans.

While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this site, BEI Resources makes no warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. BEI Resources does not warrant that such information has been confirmed to be accurate.


Back to My Search